Neurotech USA, Inc.

The company concentrates its research on novel therapies for eye diseases.

Neurotech was originally based in France, bus was transferred to the USA in 2006. The company is funded by international investors including Merlin Biosciences, Apax Partners, 3i Plc, Atlas Venture, Omega, Nexus Medical Partners and Pound Capital.

Ted Danse, President and CEO
Weng Tao, MD, PhD, CSO, VP Research & Development USA
Rich Small, VP and CFO

Bryant E. Fong
William J. Link, Ph.D.
Laurent Ganem, M.D., MBA
Lutz Giebel, Ph.D.
Ted Danse

Eberhardt Zrenner, Prof.
Jose Sahel, Prof.
Alan Bird, M.D.
Glenn Jaffe, M.D.
Barry Kuppermann, M.D., Ph.D.
David S. Boyer, M.D.
Julia A. Haller, M.D.

6 Blackstone Valley Place
Suite 500
Lincoln, RI 02865
USA
Phone: +1-401-333-3880
Fax: +1-401-333-3881

Neurotech’s Encapsulated Cell Technology (ECT) allows the controlled, continuous, long term release of therapeutic proteins directly to the retina. ECT is made of an immunoisolatory hollow fibre membrane that allows the implantation of genetically-engineered cells that continuously produce the therapeutic protein at the site of implantation. Cells within the hollow fiber membrane attach to a proprietary supportive matrix.

The company’s product NT-501 uses Neurotech’s patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF). The Phase I study of NT-501, in which 10 patients suffering from retinitis pigmentosa were involved, showed positive results in May 2005.

A Phase I study of NT-501 involving 10 patients suffering from retinitis pigmentosa has shown positive results (May 2005).

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.